Pulmonx Corporation (NASDAQ:LUNG) Given Average Recommendation of “Moderate Buy” by Analysts

Pulmonx Corporation (NASDAQ:LUNG) has been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $7.6643.

Several equities research analysts recently weighed in on LUNG shares. Stifel Nicolaus dropped their price objective on shares of Pulmonx from $16.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, July 31st. D. Boral Capital restated a “buy” rating and issued a $16.00 price target on shares of Pulmonx in a research note on Monday, September 8th. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a research note on Saturday, August 30th. Citigroup dropped their price target on shares of Pulmonx from $6.50 to $4.15 and set a “neutral” rating on the stock in a research note on Thursday, May 22nd. Finally, Wells Fargo & Company dropped their price target on shares of Pulmonx from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Friday, August 1st.

Institutional Investors Weigh In On Pulmonx

Several large investors have recently made changes to their positions in LUNG. Northern Trust Corp increased its stake in shares of Pulmonx by 2.9% in the fourth quarter. Northern Trust Corp now owns 372,659 shares of the company’s stock valued at $2,530,000 after purchasing an additional 10,433 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Pulmonx in the fourth quarter valued at approximately $43,000. Bank of America Corp DE increased its stake in shares of Pulmonx by 58.8% in the fourth quarter. Bank of America Corp DE now owns 55,237 shares of the company’s stock valued at $375,000 after purchasing an additional 20,458 shares during the period. Millennium Management LLC increased its stake in shares of Pulmonx by 26.6% in the fourth quarter. Millennium Management LLC now owns 183,069 shares of the company’s stock valued at $1,243,000 after purchasing an additional 38,425 shares during the period. Finally, ProShare Advisors LLC acquired a new position in shares of Pulmonx during the fourth quarter valued at approximately $72,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Price Performance

LUNG opened at $1.60 on Friday. The firm has a market cap of $65.20 million, a price-to-earnings ratio of -1.12 and a beta of 0.43. Pulmonx has a fifty-two week low of $1.47 and a fifty-two week high of $9.37. The company’s 50-day moving average price is $2.06 and its 200 day moving average price is $3.72. The company has a quick ratio of 4.63, a current ratio of 5.35 and a debt-to-equity ratio of 0.54.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, July 30th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.02. The firm had revenue of $23.86 million for the quarter, compared to analyst estimates of $23.46 million. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. Pulmonx has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Pulmonx will post -1.55 earnings per share for the current year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.